NCT03806179View on ClinicalTrials.gov

Study of Safety and Efficacy of Betalutin and Rituximab in Patients With FL

PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

October 4, 2018

Primary Completion Date

August 8, 2022

Study Completion Date

August 8, 2022

Conditions
Non Hodgkin LymphomaFollicular LymphomaRelapsed Follicular Lymphoma
Interventions
DRUG

10 MBq/kg Betalutin

10 MBq/kg Betalutin, lilotomab 40mg, rituximab 375 mg/m2

DRUG

15 MBq/kg Betalutin

15 MBq/kg Betalutin, lilotomab 40mg, rituximab 375 mg/m2

Trial Locations (2)

807-52

Klinika Hematoonkologie, Ostrava

N-0310

Oslo University Hospital, Oslo

Sponsors

Lead Sponsor

Nordic Nanovector

Collaborators (1)

ICON Clinical Research
All Listed Sponsors
collaborator

ICON Clinical Research

INDUSTRY

lead

Nordic Nanovector

INDUSTRY